secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001178913-25-003444
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion reports SIL204 shows up to 99.7% inhibition across 11 human cell lines, first gastric cancer data
--------------------------------------------------------------------------------

- SIL204 achieved 83.5% to 99.7% inhibition at nanomolar concentrations (IC50 23.4–85.3 nM) in 11 lines from 5 cancer types.
- Highest activity: 99.7% inhibition in NCIH2009 lung cells (G12A mutation); first gastric cancer data showed 89.2% inhibition (G12D).
- Pancreatic G12R (17% of cases) showed 91.5% inhibition (IC50 31.5 nM) in KP2 cells; expanded colorectal validation in HCT 116 (G13D).
- SIL204 now confirmed active against G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations.
- Phase 2/3 trial planned H1 2026; regulatory submissions to Israel MoH in Q4 2025 and EU in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003444/0001178913-25-003444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003444/zk2533822.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer